Leiden University Scholarly Publications

Your Search

Enabled Filters

Refine Results

Resource Type

Availability

Creation Date

Faculty

Collection

Author

Show more

Language

Search results

  • RSS Feed
(1 - 14 of 14)
Properly Downsized Annuloplasty for Functional Mitral Regurgitation: Unbeaten in the Right Patient
Braun, J. 2022
Properly Downsized Annuloplasty for Functional Mitral Regurgitation: Unbeaten in the Right Patient
Other
metadata only
Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force
Smolen, J.S.; Schoels, M.; Braun, J.; Dougados, M.; FitzGerald, O.; Gladman, D.D.; ... ; Heijde, D. van der 2018
Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force
Other
open access
Stentless bioprostheses: a versatile and durable solution in extensive aortic valve endocarditis(aEuro)
Schneider, A.W.; Hazekamp, M.G.; Versteegh, M.I.M.; Bruggemans, E.F.; Holman, E.R.; Klautz, R.J.M.; Braun, J. 2016
Stentless bioprostheses: a versatile and durable solution in extensive aortic valve endocarditis(aEuro)
Other
metadata only
The Freestyle stentless bioprosthesis is a valuable option to reconstruct the LVOT after debridement in extensive aortic valve endocarditis. It is readily available with a versatility and clinical... Show moreThe Freestyle stentless bioprosthesis is a valuable option to reconstruct the LVOT after debridement in extensive aortic valve endocarditis. It is readily available with a versatility and clinical outcome comparable with that of homografts. Although early mortality remains considerable in this high-risk group of patients, late survival is good with low rates of recurrence of endocarditis, immediate local control and good haemodynamic performance on echocardiography. Show less
PREDICTION OF EARLY RESPONSE TO ANTI-TNF THERAPY AND DISEASE ACTIVITY STATE USING THE ANKYLOSING SPONDYLITIS DISEASE ACTIVITY SCORE
Vastesaeger, N.; Wang, Y.; Inman, R.; Deodhar, A.; Hsu, B.; Rahman, M.U.; ... ; GO-RAISE Investigators 2011
PREDICTION OF EARLY RESPONSE TO ANTI-TNF THERAPY AND DISEASE ACTIVITY STATE USING THE ANKYLOSING SPONDYLITIS DISEASE ACTIVITY SCORE
Other
metadata only
IDENTIFICATION OF ANTI-TNF CANDIDATES BASED ON PREDICTED RESPONSE AND REMISSION IN ANKYLOSING SPONDYLITIS
Vastesaeoer, N.; Heijde, D. van der; Inman, R.; Wang, Y.; Deodhar, A.; Hsu, B.; ... ; GO-RAISE Investigators 2010
IDENTIFICATION OF ANTI-TNF CANDIDATES BASED ON PREDICTED RESPONSE AND REMISSION IN ANKYLOSING SPONDYLITIS
Other
metadata only
GOLIMUMAB, A NEW, HUMAN, TNF-ALPHA ANTIBODY ADMINISTERED SUBCUTANEOUSLY EVERY 4 WEEKS, IN ANKYLOSING SPONDYLITIS: 104-WEEK EFFICACY AND SAFETY RESULTS OF THE RANDOMIZED, PLACEBOCONTROLLED GO-RAISE STUDY
Braun, J.; Heijde, D. van der; Deodhar, A.; Diekman, L.; Sieper, J.; Kim, S.I.; ... ; GO-RAISE Investigators 2010
GOLIMUMAB, A NEW, HUMAN, TNF-ALPHA ANTIBODY ADMINISTERED SUBCUTANEOUSLY EVERY 4 WEEKS, IN ANKYLOSING SPONDYLITIS: 104-WEEK EFFICACY AND SAFETY RESULTS OF THE RANDOMIZED, PLACEBOCONTROLLED GO-RAISE STUDY
Other
metadata only
THE RELATIONSHIP OF BIOMARKERS AND RADIOGRAPHIC PROGRESSION IN PATIENTS WITH ANKYLOSING SPONDYLITIS TREATED WITH TNF-BLOCKERS
Baraliakos, X.; Landewe, R.; Heijde, D. van der; Listing, J.; Baker, D.; Hsu, B.; Braun, J. 2010
THE RELATIONSHIP OF BIOMARKERS AND RADIOGRAPHIC PROGRESSION IN PATIENTS WITH ANKYLOSING SPONDYLITIS TREATED WITH TNF-BLOCKERS
Other
metadata only
BASELINE AND DISEASE-RELATED CHARACTERISTICS THAT MAY PREDICT TREATMENT RESPONSE TO ETANERCEPT IN PATIENTS WITH ANKYLOSING SPONDYLITIS: ASCEND
Heijde, D. van der; Braun, J.; Vlahos, B.; Wishneski, C.; Szumski, A.; Foehl, J.; Koenig, A. 2010
BASELINE AND DISEASE-RELATED CHARACTERISTICS THAT MAY PREDICT TREATMENT RESPONSE TO ETANERCEPT IN PATIENTS WITH ANKYLOSING SPONDYLITIS: ASCEND
Other
metadata only
IDENTIFICATION OF ANTI-TNF CANDIDATES BASED ON PREDICTED RESPONSE AND REMISSION IN ANKYLOSING SPONDYLITIS
Vastesaeger, N.; Heijde, D. van der; Inman, R.; Wang, Y.; Deodhar, A.; Hsu, B.; ... ; ASSERT GO-RAISE Investigators 2010
IDENTIFICATION OF ANTI-TNF CANDIDATES BASED ON PREDICTED RESPONSE AND REMISSION IN ANKYLOSING SPONDYLITIS
Other
metadata only
ANKYLOSING SPONDYLITIS DISEASE ACTIVITY SCORE (ASDAS): DEFINING CUT-OFF VALUES FOR DISEASE ACTIVITY STATES AND IMPROVEMENT SCORES
Machado, P.; Landewe, R.; Lie, E.; Kvien, T.K.; Braun, J.; Baker, D.; Heijde, D.H.D. van der 2010
ANKYLOSING SPONDYLITIS DISEASE ACTIVITY SCORE (ASDAS): DEFINING CUT-OFF VALUES FOR DISEASE ACTIVITY STATES AND IMPROVEMENT SCORES
Other
metadata only
RADIOGRAPHIC FINDINGS AFTER 5 YEARS OF INFLIXIMAB TREATMENT IN PATIENTS WITH ANKYLOSING SPONDYLITIS
Baraliakos, X.; Heldmann, F.; Heijde, D. van der; Listing, J.; Sieper, J.; OOrtwijn, A.; ... ; Braun, J. 2010
RADIOGRAPHIC FINDINGS AFTER 5 YEARS OF INFLIXIMAB TREATMENT IN PATIENTS WITH ANKYLOSING SPONDYLITIS
Other
metadata only
Golimumab, a New, Human, TNF-alpha Antibody Administered Subcutaneously Every 4 Weeks, in Ankylosing Spondylitis: 104-Week Efficacy and Safety Results of the Randomized, Placebo-Controlled GO-RAISE Study
Braun, J.; Heijde, D. van der; Deodhar, A.; Diekman, L.; Sieper, J.; Kim, S.I.; ... ; Inman, R. 2010
Golimumab, a New, Human, TNF-alpha Antibody Administered Subcutaneously Every 4 Weeks, in Ankylosing Spondylitis: 104-Week Efficacy and Safety Results of the Randomized, Placebo-Controlled GO-RAISE Study
Other
metadata only
THE ANKYLOSING SPONDYLITIS DISEASE ACTIVITY SCORE IN SUBJECTS TREATED WITH ETANERCEPT (ETN) OR SULFASALAZINE: COMPARISON WITH STANDARD EFFICACY MEASURES
Heijde, D. van der; Braun, J.; Sieper, J.; Wishneski, C.; Vlahos, B.; Szumski, A.; ... ; Koenig, A. 2010
THE ANKYLOSING SPONDYLITIS DISEASE ACTIVITY SCORE IN SUBJECTS TREATED WITH ETANERCEPT (ETN) OR SULFASALAZINE: COMPARISON WITH STANDARD EFFICACY MEASURES
Other
metadata only
GOLIMUMAB, A NEW HUMAN TNF-alpha ANTIBODY ADMINISTERED SUBCUTANEOUSLY EVERY 4 WEEKS, IN ANKYLOSING SPONDYLITIS: 104-WEEK EFFICACY AND SAFETY RESULTS OF THE RANDOMIZED, PLACEBO-CONTROLLED GO-RAISE STUDY
Braun, J.; Heijde, A.D. van der; Deodhar, L.; Diekman, J.; Sieper, S.I.; Kim, A.; ... ; GO-RAISE 2010
GOLIMUMAB, A NEW HUMAN TNF-alpha ANTIBODY ADMINISTERED SUBCUTANEOUSLY EVERY 4 WEEKS, IN ANKYLOSING SPONDYLITIS: 104-WEEK EFFICACY AND SAFETY RESULTS OF THE RANDOMIZED, PLACEBO-CONTROLLED GO-RAISE STUDY
Other
metadata only